Clinical Trials Directory

Trials / Completed

CompletedNCT03066167

Validation of Instruments Used for Assessment of Dysphagia in Patients With Esophageal Cancer

Status
Completed
Phase
Study type
Observational
Enrollment
64 (actual)
Sponsor
Vastra Gotaland Region · Other Government
Sex
All
Age
Healthy volunteers
Accepted

Summary

This study validates 3 well known dysphagia scores for dysphagia due to malignancies of the oesophagus and gastro-oesophageal junction and to the Swedish language.

Detailed description

In the present study, our aim was to firstly, validate 3 commonly used scales for use in patients with dysphagia due to malignancy, and secondly, to validate them in the Swedish language. The 3 scales were: The Watson dysphagia scale, which was developed in studies on surgical treatment of reflux disease. It consists of questions about food with 9 different viscosity and solidity and the patient answer if they have problems with a specific food: never, sometimes or always when ingesting this. The scores are added and provides a range of 0-45 where 45 is the worst possible dysphagia. The Ogilvie score is a 5-graded scale 0-4 where 4 is total inability to swallow. The Goldschmid score is graded from 0-5 where 0 is inability to swallow and 5 is normal function. QoL was measured with validated instruments originating from the European Organization for Research and Treatment of Cancer (EORTC), which has a generic instrument that measures global QoL in patients with cancer (QLQ-C30) and a more symptom-specific instrument that is developed for cancer in the oesophagus and stomach (QLQ-OG25). These are well known, validated instruments that also have normal reference values for the healthy population. The symptom specific instrument QLQ-OG25 includes a dysphagia module consisting of 3 questions which is validated to malignant disease and food intake with the help of expert groups and deep interviews with patients.

Conditions

Interventions

TypeNameDescription
OTHERValidation of different dysphagia scores

Timeline

Start date
2010-11-01
Primary completion
2020-07-23
Completion
2020-07-23
First posted
2017-02-28
Last updated
2020-07-28

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT03066167. Inclusion in this directory is not an endorsement.